Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Kailera reports Zepbound-rivaling weight loss in obesity phase 2
Kailera and partner Jiangsu Hengrui Pharmaceuticals linked the injectable GLP-1/GIP receptor dual agonist to 22.8% mean weight loss after 36 weeks.
Nick Paul Taylor
Jan 13, 2025 10:20am
Novo bets $190M near-term on AI pact in obesity, diabetes
Jan 8, 2025 8:00am
Metsera links GLP-1 drug to 11% weight loss after 12 weeks
Jan 7, 2025 8:32am
Big Pharma layoff rounds jump 281% in 2024
Jan 3, 2025 3:29pm
Novo stock crashes after CagriSema misses weight-loss goal
Dec 20, 2024 8:15am
Antag secures $84M series A for GLP-1 add-on
Dec 4, 2024 3:00am
